000			01470 a2200421 4500
005			20250518080339.0
264		0	_c20210104
008			202101s 0 0 eng d
022			_a1873-2364
024	7		_a10.1016/j.nmd.2019.11.007 _2doi
040			_aNLM _beng _cNLM
100	1		_avan Kooten, H A
245	0	0	_aDiscontinuation of enzyme replacement therapy in adults with Pompe disease: Evaluating the European POmpe Consortium stop criteria. _h[electronic resource]
260			_bNeuromuscular disorders : NMD _c01 2020
300			_a59-66 p. _bdigital
500			_aPublication Type: Evaluation Study; Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aClinical Decision-Making
650	0	4	_aEnzyme Replacement Therapy _xadverse effects
650	0	4	_aFemale
650	0	4	_aGlycogen Storage Disease Type II _xdrug therapy
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNetherlands
650	0	4	_aOutcome and Process Assessment, Health Care
650	0	4	_aPractice Guidelines as Topic _xstandards
650	0	4	_aProspective Studies
700	1		_aHarlaar, L
700	1		_avan der Beek, N A M E
700	1		_avan Doorn, P A
700	1		_avan der Ploeg, A T
700	1		_aBrusse, E
773	0		_tNeuromuscular disorders : NMD _gvol. 30 _gno. 1 _gp. 59-66
856	4	0	_uhttps://doi.org/10.1016/j.nmd.2019.11.007 _zAvailable from publisher's website
999			_c30492853 _d30492853